Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitis image

Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjects with moderate to severe atopic dermatitis.

Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that plays a key role in the pathogenesis of moderate to severe atopic dermatitis.

“We are advancing the development of nemolizumab as planned. The Phase 2 results  showed clear clinical benefits, adding to the growing scientific evidence that the IL-31 pathway may be an important driver in atopic dermatitis. We are committed to continuing our work to bring new therapies to patients with moderate-to-severe atopic dermatitis,” said Thibaud Portal PhD, Galderma Global Vice President, Prescription medicines.

Earlier this year, Galderma presented the final results from the Phase 2b study of nemolizumab in patients with moderate-to-severe atopic dermatitis at the 2019 American Academy of Dermatology Annual Meeting late-breaking session and published in the Journal of Allergy and Clinical Immunology in August 20191